RxDoctor Payments Data

Rebecca Lancaster

Medical · Kenly, NCNPI 1548222755

Payments from drug & device makers

$1,503in general payments, 2019–2025

Across 59 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$731
  • Tarsus Pharmaceuticals, Inc.$263
  • Mallinckrodt Hospital Products Inc.$153
  • Oyster Point Pharma, Inc.$90
  • Johnson & Johnson Vision Care, Inc.$73
  • Novo Nordisk$57
  • plus $137 from 4 others

What the payments were for

  • Food & beverage$1,503100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,503 in reported general payments places this provider in the 70th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$113,083
Medicare patients
774
Services billed
1,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine252$294,299
LumiganBimatoprost265$111,938
XiidraLifitegrast35$54,660
TyrvayaVarenicline Tartrate35$39,195
CombiganBrimonidine Tartrate/Timolol82$25,892
Alphagan PBrimonidine Tartrate57$21,354
Fluorometholone223$15,727
Cyclosporine35$15,456
Brimonidine Tartrate242$13,511
Latanoprost834$13,049
CequaCyclosporine12$12,607
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol50$9,713
IlevroNepafenac26$9,621
Loteprednol Etabonate49$8,568
RocklatanNetarsudil Mesylat/Latanoprost19$7,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$731$453,482656 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$45$57,90846 claims
Oyster Point Pharma, Inc.Tyrvaya$90$39,19535 claims
Sun Pharmaceutical Industries Inc.Cequa$21$12,60712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 878 medical providers in North Carolina.

Other medical in Kenly

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →